MCID: HYP025
MIFTS: 48

Hyperphosphatemia

Categories: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

MalaCards integrated aliases for Hyperphosphatemia:

Name: Hyperphosphatemia 12 28 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050459
MeSH 41 D054559
NCIt 46 C113750
SNOMED-CT 64 20165001
UMLS 69 C0085681

Summaries for Hyperphosphatemia

MalaCards based summary : Hyperphosphatemia is related to tumoral calcinosis, hyperphosphatemic, familial and hypoparathyroidism, familial isolated. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Endochondral Ossification. The drugs Alendronate and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and liver, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 72 Hyperphosphatemia is an electrolyte disturbance in which there is an abnormally elevated level of... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial 33.7 FGF23 GALNT3 KL
2 hypoparathyroidism, familial isolated 32.0 GCM2 PTH
3 pseudohypoparathyroidism, type ib 31.7 GNAS PTH STX16
4 hyperostosis 30.7 FGF23 GALNT3 KL
5 hypocalcemia, autosomal dominant 1 30.6 CASR GCM2 GNAS VDR
6 familial tumoral calcinosis 30.4 FGF23 GALNT3 KL
7 calcinosis 30.2 FGF23 GALNT3 KL MGP
8 hypophosphatemia 30.1 FGF23 PTH SLC34A1
9 chronic kidney failure 29.8 CASR FGF23 PTH VDR
10 hypercalcemia, infantile, 1 29.6 CASR PTH VDR
11 kidney disease 29.6 CASR FGF23 PTH
12 uremia 29.4 CASR PTH VDR
13 hypoparathyroidism 29.2 CASR FGF23 GCM2 PTH
14 secondary hyperparathyroidism of renal origin 29.1 CASR FGF23 PTH VDR
15 hyperparathyroidism 29.0 CASR FGF23 GCM2 PTH VDR
16 calciphylaxis 28.7 CASR FGF23 PTH VDR
17 osteoporosis 26.5 CASR FGF23 KL MGP PTH RUNX2
18 hyperphosphatemia, polyuria, and seizures 12.0
19 pseudohypoparathyroidism, type ia 10.9
20 hypoparathyroidism-retardation-dysmorphism syndrome 10.9
21 pseudohypoparathyroidism, type ic 10.9
22 tracheal calcification 10.4 FGF23 KL
23 hypophosphatemic rickets, autosomal dominant 10.4 FGF23 GALNT3
24 oncogenic osteomalacia 10.4 FGF23 PTH
25 arterial calcification of infancy 10.4 FGF23 GALNT3
26 impaired renal function disease 10.4 FGF23 PTH
27 metaphyseal chondrodysplasia, jansen type 10.3 FGF23 PTH
28 chief cell adenoma 10.3 GCM2 PTH
29 albright's hereditary osteodystrophy 10.3 GNAS STX16
30 peritonitis 10.2
31 arterial calcification, generalized, of infancy, 1 10.2
32 leukemia 10.2
33 pseudopseudohypoparathyroidism 10.2 GNAS PTH STX16
34 urinary system disease 10.2 FGF23 KL PTH
35 metal metabolism disorder 10.1 GNAS PTH STX16
36 pseudohypoparathyroidism 10.1 GNAS PTH STX16
37 pulmonary alveolar microlithiasis 10.1 FGF23 PTH SLC34A1
38 fanconi syndrome 10.1 PTH SLC34A1
39 osseous heteroplasia, progressive 10.1 GNAS RUNX2
40 lymphoblastic leukemia 10.1
41 glucocorticoid-induced osteoporosis 10.0 PTH RUNX2
42 hypervitaminosis d 10.0 FGF23 GALNT3 KL PTH
43 spondylosis 10.0 KL PTH VDR
44 myeloma, multiple 10.0
45 lactic acidosis 10.0
46 ischemic bone disease 10.0 PTH RUNX2
47 hypocalciuric hypercalcemia, familial, type ii 10.0 CASR PTH
48 hypophosphatemic rickets, x-linked recessive 10.0 FGF23 SLC34A1 VDR
49 endotheliitis 9.9
50 familial hypocalciuric hypercalcemia 9.9 CASR PTH

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 FGF23 GNAS GALNT3 CASR RUNX2 MGP
2 homeostasis/metabolism MP:0005376 10.21 FGF23 GNAS GALNT3 CASR GCM2 RUNX2
3 cardiovascular system MP:0005385 10.2 FGF23 GNAS GALNT3 KL RUNX2 MGP
4 endocrine/exocrine gland MP:0005379 10.15 GCM2 FGF23 GNAS GALNT3 CASR KL
5 cellular MP:0005384 10.14 GCM2 GALNT3 CASR KL RUNX2 GNAS
6 craniofacial MP:0005382 10.07 GCM2 GNAS GALNT3 KL RUNX2 PTH
7 hematopoietic system MP:0005397 10.06 FGF23 GALNT3 CASR KL RUNX2 GNAS
8 immune system MP:0005387 10.01 FGF23 GALNT3 CASR KL RUNX2 GNAS
9 digestive/alimentary MP:0005381 9.99 FGF23 GALNT3 CASR KL RUNX2 VDR
10 mortality/aging MP:0010768 9.96 GCM2 FGF23 GNAS CASR KL RUNX2
11 integument MP:0010771 9.91 FGF23 GNAS GALNT3 CASR KL RUNX2
12 limbs/digits/tail MP:0005371 9.87 FGF23 GNAS GALNT3 KL RUNX2 PTH
13 muscle MP:0005369 9.76 GNAS GALNT3 CASR KL RUNX2 MGP
14 renal/urinary system MP:0005367 9.61 FGF23 GNAS GALNT3 CASR GCM2 MGP
15 skeleton MP:0005390 9.4 GNAS GALNT3 CASR GCM2 FGF23 RUNX2

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
2
Calcium acetate Approved, Investigational Phase 4,Phase 3,Phase 1 62-54-4
3
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2 471-34-1
4
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1 52757-95-6, 152751-57-0 3085017
5
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
6
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
7
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
8
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
10
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
11
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
13
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 59-67-6 938
14
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 98-92-0 936
15
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
16 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
17 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
18 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Ferric Compounds Phase 4,Phase 3,Phase 2
20 Hematinics Phase 4,Phase 3,Phase 2
21 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Hormones Phase 4,Phase 3
23 Antacids Phase 4,Phase 3,Phase 2
24 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Ergocalciferols Phase 4,Phase 2
27 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
28 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
29 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
30 Hydroxycholecalciferols Phase 4
31 Vasoconstrictor Agents Phase 4,Phase 2
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
33 Anticholesteremic Agents Phase 4
34 Antimetabolites Phase 4,Phase 2,Phase 1
35 Atorvastatin Calcium Phase 4 134523-03-8
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
37 Hypolipidemic Agents Phase 4,Phase 2,Phase 1
38 Lipid Regulating Agents Phase 4,Phase 2,Phase 1
39 Liver Extracts Phase 4
40 Calcimimetic Agents Phase 4
41 Cinacalcet Hydrochloride Phase 4
42 Hormone Antagonists Phase 4,Phase 3
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
44 Nicotinic Acids Phase 4,Phase 2,Phase 1
45 Vasodilator Agents Phase 4,Phase 2,Phase 1
46 Vitamin B Complex Phase 4,Phase 2,Phase 1
47 Protective Agents Phase 4,Phase 2
48 Antioxidants Phase 4
49 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
50 Calciferol Nutraceutical Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 167)

# Name Status NCT ID Phase Drugs
1 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
2 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
3 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
4 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
5 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
6 Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease Completed NCT00160121 Phase 4 Lanthanum carbonate
7 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
8 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
9 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
10 Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients Completed NCT01427907 Phase 4 Calcium acetate oral solution (COS);Sevelamer carbonate
11 Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00091481 Phase 4 Zemplar
12 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
13 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
14 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
15 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Recruiting NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
16 Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Recruiting NCT03256838 Phase 4 Ferric Citrate
17 Phophate Lowering Trial Recruiting NCT02209636 Phase 4 Lanthanum carbonate;placebo;Ascorbic Acid;Nitroglycerin
18 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
19 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
20 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Not yet recruiting NCT03079869 Phase 4 Ferric Citrate
21 Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 Terminated NCT00452478 Phase 4 Lanthanum carbonate
22 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
23 Vitamin D and Carboxy PTH Fragments in Coronary Calcification Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
24 Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction Unknown status NCT01357317 Phase 3 Phosphorus binder
25 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
26 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
27 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
28 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
29 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
30 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
31 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
32 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
33 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
34 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
35 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
36 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
37 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
38 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
39 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
40 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
41 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
42 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3 MCI-196;Placebo
43 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
44 A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Completed NCT01324128 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate;PA21-1 (1.25 g tablet containing 250 mg iron)
45 A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Completed NCT01464190 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate
46 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
47 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3 ferric citrate
48 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets
49 A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis Completed NCT01191255 Phase 3 ferric citrate, ca acetate, sevelamer carbonate, placebo
50 An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis Completed NCT00681941 Phase 3 Sevelamer carbonate (Renvela®)

Search NIH Clinical Center for Hyperphosphatemia

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

# Genetic test Affiliating Genes
1 Hyperphosphatemia 28

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

38
Kidney, Bone, Liver, Smooth Muscle, Heart, Endothelial, Colon

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 458)
# Title Authors Year
1
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. ( 29340316 )
2018
2
Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. ( 29295646 )
2018
3
Hyperphosphatemia is associated with high mortality in severe burns. ( 29315336 )
2018
4
Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients. ( 28975589 )
2017
5
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. ( 28533541 )
2017
6
Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. ( 28321403 )
2017
7
Activation of the Nrf2-ARE Signaling Pathway Prevents Hyperphosphatemia-Induced Vascular Calcification by Inducing Autophagy in Renal Vascular Smooth Muscle Cells. ( 28513870 )
2017
8
Hyperphosphatemia, a Cause of High Anion Gap Metabolic Acidosis: Report of a Case and Review of the Literature. ( 28450695 )
2017
9
Hyperphosphatemia induces senescence in human endothelial cells by increasing endothelin-1 production. ( 28857396 )
2017
10
Analysis of Hypo- and Hyperphosphatemia in an Intensive Care Unit Cohort. ( 28525508 )
2017
11
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. ( 28078600 )
2017
12
Surface-Engineered Blood Adsorption Device for Hyperphosphatemia Treatment. ( 28799951 )
2017
13
Educational nursing intervention to reduce the hyperphosphatemia in patients on hemodialysis. ( 28226039 )
2017
14
A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway. ( 29270533 )
2017
15
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. ( 28777915 )
2017
16
Tumor lysis syndrome with massive hyperphosphatemia and hyperuricemia. ( 29225880 )
2017
17
Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. ( 28182142 )
2017
18
A Dialysis Patient With Hyperphosphatemia, Hyperkalemia, and Azotemia Without an Excessive Intake. ( 29142992 )
2017
19
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. ( 28550969 )
2017
20
Uremic Tumoral Calcinosis Resolved by Improvements in Hyperphosphatemia. ( 28626193 )
2017
21
Effect of Vitamin D Supplementation on Delayed Hyperphosphatemia in Pediatric Acute Lymphoblastic Leukemia Patients During Induction Chemotherapy. ( 28469534 )
2017
22
Transient hyperphosphatemia in a child with nephrolithiasis and severe prematurity. ( 28325562 )
2017
23
Hyperphosphatemia in a patient with spinal cord injury who received etidronate for the treatment of heterotopic ossification. ( 28616259 )
2017
24
Antibody-mediated inhibition of EGFR reduces phosphate excretion and induces hyperphosphatemia and mild hypomagnesemia in mice. ( 28292888 )
2017
25
Cost-effectiveness of dedicated dietitians for hyperphosphatemia management among hemodialysis patients in Lebanon: results from the Nutrition Education for Management of Osteodystrophy trial. ( 28657451 )
2017
26
Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode". ( 28528515 )
2017
27
Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients. ( 28218647 )
2017
28
Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. ( 27751671 )
2016
29
Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience. ( 26855510 )
2016
30
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. ( 27837149 )
2016
31
Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease. ( 27512294 )
2016
32
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. ( 26668024 )
2016
33
Transient hyperphosphatemia: a benign laboratory disorder in a boy with Gitelman syndrome. ( 27737396 )
2016
34
Phenotypic and Genotypic Characterization and Treatment of a Cohort with Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. ( 27164190 )
2016
35
Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients. ( 27900961 )
2016
36
Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. ( 27389681 )
2016
37
Acute tumoral calcinosis due to severe hyperphosphatemia in a maintenance hemodialysis patient. ( 28508978 )
2016
38
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. ( 27651467 )
2016
39
Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. ( 27121505 )
2016
40
Ornithine is a key mediator in hyperphosphatemia-mediated human umbilical vein endothelial cell apoptosis: Insights gained from metabolomics. ( 26773858 )
2016
41
Spurious Hyperphosphatemia: A Diagnostic and Therapeutic Challenge. ( 26706383 )
2016
42
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( 27933339 )
2016
43
Severe hyperphosphatemia after oral laxative administration in a 7-year-old patient. ( 27922249 )
2016
44
Treating hyperphosphatemia - current and advancing drugs. ( 27643443 )
2016
45
Short-Term PTH(1-34) Therapy in Children to Correct Severe Hypocalcemia and Hyperphosphatemia due to Hypoparathyroidism: Two Case Studies. ( 27957353 )
2016
46
Hyperphosphatemia Management in Patients with Chronic Kidney Disease. ( 27330380 )
2016
47
Effect of hyperphosphatemia on gene expression of the Na-Pi cotransporter in rats. ( 26782594 )
2015
48
Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. ( 26180236 )
2015
49
Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization. ( 25899975 )
2015
50
Hyperphosphatemia Is an Independent Risk Factor for Mortality in Critically Ill Patients: Results from a Cross-Sectional Study. ( 26252874 )
2015

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 8.92 CASR GNAS KL SLC34A1

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor signaling pathway GO:0008543 9.67 FGF23 GALNT3 KL
2 skeletal system development GO:0001501 9.62 GNAS PTH RUNX2 VDR
3 embryonic cranial skeleton morphogenesis GO:0048701 9.59 GNAS RUNX2
4 positive regulation of bone mineralization GO:0030501 9.58 KL PTH
5 response to cadmium ion GO:0046686 9.58 PTH SLC34A1
6 endochondral ossification GO:0001958 9.57 GNAS RUNX2
7 regulation of bone mineralization GO:0030500 9.56 FGF23 MGP
8 cellular calcium ion homeostasis GO:0006874 9.56 CASR GCM2 PTH VDR
9 response to lead ion GO:0010288 9.55 PTH SLC34A1
10 energy reserve metabolic process GO:0006112 9.54 GNAS KL
11 response to magnesium ion GO:0032026 9.52 FGF23 SLC34A1
12 cellular response to vitamin D GO:0071305 9.51 CASR FGF23
13 cellular response to parathyroid hormone stimulus GO:0071374 9.48 FGF23 SLC34A1
14 response to fibroblast growth factor GO:0071774 9.46 CASR PTH
15 ossification GO:0001503 9.46 CASR MGP RUNX2 SLC34A1
16 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.43 FGF23 KL
17 phosphate ion homeostasis GO:0055062 9.4 FGF23 SLC34A1
18 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.37 FGF23 VDR
19 cellular phosphate ion homeostasis GO:0030643 9.13 FGF23 GCM2 SLC34A1
20 response to parathyroid hormone GO:0071107 8.8 GNAS PTH SLC34A1

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 8.62 FGF23 KL

Sources for Hyperphosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....